Methods: Seventy-three patients with HBeAg-negative ACLF were enrolled. Serum levels of HBsAg, HBV DNA and biochemical items were detected before treatment. Meanwhile the Model for End-stage Liver Disease (MELD) score was calculated based on serum TBiL, INR and Creatinine. The correlation

of HBsAg level with HBV DNA level, biochemical items BAY 80-6946 nmr and MELD score were analyzed. Results: Serum levels of HBsAg, HBV DNA, ALT, AST, TBiL, INR and Creatinine were 5473 ± 3268 COI, 5.29 ± 1.81 lg copies/ mL, 858 ± 930 IU/L, 536 ± 601 IU/L, 450.05 ± 204.95 umol/L, 2.55 ± 0.84 and 69.4 ± 27.1 mmol/L in sequence. And MELD scores were 25.17 ± 4.93. HBsAg level was significant correlation with ALT(r= -0.473, P= 0.041) and AST (r= -0.480, P= 0.038). No significant correlation PLX4032 in vitro was found among HBsAg level and HBV DNA, TBiL, INR, Creatinine and MELD score (all P&gt 0.05). Conclusion: For HBeAg-negative ACLF patient without treatment, the serum level of HBsAg isn’t directly correlation with HBV DNA level. It results from a balance between virus biology and the host’s immune system response lesion. Key Word(s): 1. ACLF; 2. HBsAg level; 3. Correlation; Presenting Author: IOAN SPOREA Additional Authors: ROXANA SIRLI, SIMONA BOTA,

ALEXANDRA DELEANU, ISABEL DAN, ALINA POPESCU, ANA JURCHIS, MELANIA ARDELEAN, NADIA CORNU, MIRELA DANILA Corresponding Author: IOAN SPOREA Affiliations: Department of Gastroenterology and Hepatology, “Victor Babeș” University of Medicine and Pharmacy Timișoara, Romania Objective: to evaluate the usefulness of Transient Elastography (TE) for the evaluation

of subjects chronically infected with hepatitis B virus (HBV). Methods: Our study included 604 successive patients chronically infected with this website HBV, evaluated in our Department between June 2007-December 2012 (293 HBV non-replicative carriers, 217 patients with chronic hepatitis B evaluated by liver biopsy – LB, and 94 patients with liver cirrhosis diagnosed by means of biological, clinical, ultrasonographic and/or endoscopic criteria). In each patient we performed liver stiffness measurements (LSMs) by using a FibroScan device (Echosens, Paris, France). Ten valid LSMs were performed in each patient, by using the standard M-probe; a median value was calculated and expressed in kiloPascals (kPa). TE measurements were considered reliable if 10 valid measurements could be acquired with at least 60% success rate and less than 30% interquartile range interval. Results: Reliable LSM measurements were obtained in 84.1% of patients. The mean value of LSMs in HBV carries was 5.8±2.5 kPa (median 5.4). In patients with LB, the mean values of LSMs (kPa) according to the different stages of fibrosis were: F0-1 – 6.2±1.8 (median 6), F2-7.1±1.2 (median 6.8), F3-9.5±3.9 (median 8.8) and F4-18.4±8.8 (median 15.9). The best TE cut-offs for predicting various stages of liver fibrosis were: F≥2 – 7.8 kPa (AUROC=0.663), F≥3 – 8.6 kPa (AUROC=0.771), F=4-13.